Home Analyst Ratings SQZ Biotechnologies gets fresh Outperform rating from Evercore ISI Group

SQZ Biotechnologies [SQZ] gets fresh Outperform rating from Evercore ISI Group

Evercore ISI Group launched its SQZ Biotechnologies [SQZ] rating to the equivalent of Outperform and assigned the price target of $nan, in a research note dated 2021-01-08. That figure represents around a nan% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with BTIG Research’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late November. Meanwhile, BofA Securities had launched its coverage on SQZ with “Buy”, in a research note produced for clients November 24, 2020.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

SQZ Price Performance

On Wall Street, SQZ Biotechnologies Company [NYSE:SQZ] finished Thursday’s session down -1.94% at $29.32. The stock went up to $30.52 at the same session while its lowest single day price was $28.1495. In the last five days, it saw a fall of about -2.40%, SQZ Biotechnologies Company shares gained by almost 1.17% since the beginning of the year. However, the share price has dropped to as low as -19.65% below its one year high.

SQZ Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 28.14 level, and in case of violation of this particular level, it will cause more drop to 26.96 level. On the upper level, 31.70 is still the key resistance. The stock may increase to the subsequent resistance at 30.51. The Relative Strength Index (RSI) pinned on the 14-day chart is 55.83, implying a neutral technical stance while the MACD stands at 0.67, meaning price will decrease in the next trading period. Percent R indicator moved to 52.85%, implying low price movement. Stochastic %K at 47.88% suggest selling the stock.

What is the short interest in SQZ Biotechnologies Company?

Short interest in the SQZ Biotechnologies Company stock has plunged, decreasing by 68130.0 shares to total 79270.0 shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 11140.0, data from Yahoo Finance shows. The increase of 85.95% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 0.43% of the overall float for the stock.

SQZ Biotechnologies Company’s Biggest Shareholders: Who Owns SQZ Biotechnologies Company [SQZ]?

Filings by Temasek Holdings Pte Ltd. showed that the firm now holds a total of 2,513,924 shares or roughly 10.49% of the outstanding SQZ shares. This means their shares have increased by 625,000 from the 2,513,924 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Invus Public Equities Advisors LL updated stake is worth $49,795,548.

SQZ Earnings Forecast For The Current Quarter

SQZ Biotechnologies Company [SQZ] is expected to report earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $3.5M and an earnings per share of -$0.75 for Dec 2020. Looking further ahead, the company is expected to report revenue of $8.94M at an EPS of -$0.4 for Mar 2021. The estimates represent -3.00% and 52.90% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

SQZ Earnings Estimates For The Current Year

For the financial year, SQZ Biotechnologies Company [NYSE:SQZ] is expected to bring in revenue of $19.38M. In terms of EPS for the 2020, estimate put it at -5.05.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Prompted INVO Biosciences’ After-Hours Rally?

A spike in INVO Bioscience, Inc's (NASDAQ: INVO) stock price after-hours drove its price up 83.28% on Monday. In regular sessions, through the end...

The Opgen (OPGN) Stock Is High Today, Reason?

OpGen, Inc. (Nasdaq: OPGN), a company that makes use of the power of molecular diagnostics and bioinformatics to treat infectious diseases, is showing strength...

Why Nano Dimension (NNDM) Leapt 7% In Aftermarket Trading On Friday?

After-hours trading on Friday saw Nano Dimension Corp (Nasdaq: NNDM) hit $7.97 a share rising 4.73%. The stock saw a decline of -2.31% to...

What Caused The Anchiano Therapeutics (ANCN) To Continue Rally After-Hours?

The clinical-stage biotech company Anchiano Therapeutics Ltd. (Nasdaq: ANCN) saw its stock rising 40.12% in after-hours trades on Friday. The price of the company’s...

Are The Financial Results Weighing On Senseonics (SENS) Stock In Premarket Today?

Shares of medical technology Senseonics Holdings, Inc. (NYSE American: SENS) has been declining -9.67% in pre-market session today falling to a price level of...

Tron (TRX) Working Hard on DeFi Development; Where is TRX Heading?

Tron 2021 Global DeFi Hackathon developer contest is one of its $120 million TRON DeFi Entrepreneurial Alliance Support Program.  TRON (TRX) is making sure that it...

Mark Cuban backs Dogecoin (DOGE) and says Dallas Mavericks are the largest merchant of Meme Coin worldwide

After Elon Musk, Cuban comes out in favor of the meme coin. Dogecoin (DOGE) is one of the most anticipated cryptocurrencies of the future. Back...

The Opgen (OPGN) Stock Is High Today, Reason?

OpGen, Inc. (Nasdaq: OPGN), a company that makes use of the power of molecular diagnostics and bioinformatics to treat infectious diseases, is showing strength...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.